Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
Arbutus Biopharma Corp (ABUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 , in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tolerated and appears to result in continued HBsAg declines in some patients First patient dosed in additional arm of Phase 2a clinical trial combining imdusiran, VTP-300, NA therapy and nivolumab – advancing towards goal of further stimulating host HBV-associated immunity Cash runway into the first quarter of 2025 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 03, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutica...",
"Corporate Presentation"
07/12/2023 8-K Quarterly results
07/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Appoints Two New Executives Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement litigations. Both Dr. Sims and Mr. Naftzger will report directly to William Collier, Arbutus President and Chief Executive Offic..."
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 WARMINSTER, Pa., June 07, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver Congress 2023 taking place June 21 - 24, 2023 in Vienna, Austria. The accepted abstracts for poster presentations are as follows: Abstract Number: 4112 Title: Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection Presenter: Prof. Man-Fung Yuen Presentati..."
05/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "EXHIBIT 10.1 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN"
05/04/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech"
03/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of AB-161, Arbutus’ oral RNA destabilizer. AB-161 is being developed for use in an all-oral combination regimen to potentially provide a functional cure for patients with hepatitis B virus . “We are pleased to move AB-161 into Phase 1 clinical development,” said William Collier, President and C..."
03/02/2023 8-K Quarterly results
Docs: "Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase 1 clinical trial for oral M pro coronavirus candidate, AB-343, expected in the second half of 2023 Strengthened financial position – cash runway into Q4 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., March 02, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific vi...",
"Corporate Presentation"
01/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Arbutus Announces Resignation of Board Member WARMINSTER, Pa., Jan. 27, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified the Company of her intention to resign from the Company’s Board of Directors, effective February 26, 2023. Dr. Tran will be transitioning into public service commencing February 27, 2023, that will preclude her participation on the Arbutus and other pharmaceutical and biotechnology Boards. Dr. Tran joined the Arbutus Board of Directors in November 2021 and served as a member of the Executive Compensation and Human Resources Committee. During her tenure, she has contributed her exte..."
01/05/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Announces 2023 Corporate Objectives and Provides Financial Update Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., Jan. 05, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced its 2023 corporate objectives and provided a financial update. William Collier, President and CEO of Arbutus Biopharma, stated, “Building upon our accomplishments in 2022, we are poised in this coming year t...",
"Corporate Presentation January 5, 2023"
12/13/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729 WARMINSTER, Pa., Aug. 30, 2022 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,427,823, which provides composition of matter patent protection for Arbutus’ AB-729 RNAi therapeutic product. The patent is expected to provide Arbutus with exclusivity for AB-729 out to at least April 2038. “We are pleased to be granted this key patent by the USPTO which expands our intellectual property estate and adds a level of protection for a fundamental asset of our chronic hepatitis B virus portf..."
08/04/2022 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update Key milestones across our chronic hepatitis B virus and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates. “This quarter we presented data at the EASL ILC which highlighted the advancements we have made in developing our lead RNAi therapeutic AB-729, capsid inhibitor AB-836, and PD-L1 inhi..."
07/20/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy